DAR AL DAWA DEVELOPMENT AND INVESTMENT CO. LTD. Dar Al Dawa Development and Investment Co. Ltd. Share Price
Equities
DADI
JO4101211012
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.31 JOD | -2.24% |
|
-6.43% | -0.76% |
| Sales 2022 | 60.36M 85.25M 7.11B | Sales 2023 | 74.88M 106M 8.82B | Capitalization | 46.2M 65.25M 5.44B |
|---|---|---|---|---|---|
| Net income 2022 | 2M 2.82M 236M | Net income 2023 | 3M 4.24M 353M | EV / Sales 2022 | 1.04 x |
| Net Debt 2022 | 25.39M 35.86M 2.99B | Net Debt 2023 | 26.46M 37.37M 3.12B | EV / Sales 2023 | 0.97 x |
| P/E ratio 2022 |
16.1
x | P/E ratio 2023 |
14.6
x | Employees | 1,067 |
| Yield 2022 |
4.67% | Yield 2023 |
-
| Free-Float | 43.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.24% | ||
| 1 week | -6.43% | ||
| Current month | +0.77% | ||
| 1 month | +0.77% | ||
| 3 months | +1.55% | ||
| 6 months | +9.17% | ||
| Current year | -0.76% |
1 week
1.30
1.41
1 month
1.271.42
Current year
1.251.42
1 year
0.991.42
3 years
0.951.54
5 years
0.911.54
10 years
0.893.71
| Managers | Title | Age | Since |
|---|---|---|---|
Khaled Harb
CEO | Chief Executive Officer | 57 | 15/22/15 |
| Director of Finance/CFO | 46 | - | |
Mohammed Al-Sous
COO | Chief Operating Officer | 61 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 28/18/28 | |
| Chairman | 62 | - | |
Akram Jarrab
CHM | Chairman | 76 | 19/18/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 1.31 | -2.24% | 32,385 |
| 23/24/23 | 1.34 | 0.00% | 63,980 |
| 22/24/22 | 1.34 | 0.00% | 24,830 |
| 21/24/21 | 1.34 | -4.29% | 172,202 |
| 18/24/18 | 1.4 | -0.71% | 12,171 |
End-of-day quote Amman S.E., April 24, 2024
More quotes
Dar Al Dawa Development and Investment Company PSC is a Jordan-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical and consumer health products. The Companyâs main activities are producing medical, chemical and pharmaceutical products, and importing pharmaceutical products. The Company operates an integrated network of 11 manufacturing facilities spread across Jordan, Middle East and North Africa region, as well as Romania. Its Pharmaceutical Development Unit focuses on the process developing of various dosage forms including tablets, capsules, liquids, dry suspensions, suppositories, creams, ointments, gels, parenterals, ophthalmic and nasal preparations. The Analytical Research unit engages in the analytical method development, validation, physiochemical characterization and stability studies.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -0.76% | 64.68M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- DADI Stock
